Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of JNJ-64417184 and Rilematovir in Healthy Adults
NCT04090086Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilematovir and JNJ-64417184 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Observed Plasma Analyte Concentration at end of dosing interval (Ctrough) at Day 7, Maximum Observed Plasma Analyte Concentration at Day 7 and 1 more. Started Sep 2019; status: completed.
02
Drugs
rilematovirJNJ-64417184
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04090086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090086.